GOGraham David Ogle

Graham David Ogle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Graham David Ogle has a total of 293 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh

    by Margaret L. Prust, Christina M. Lalama, Sylvia Kehlenbrink, Olatubosun Akinnola Akinola, Renatus Nyarubamba, Ajmina Hasan Flabe, Abigail Foulds, Graham D. Ogle, Edna Majaliwa, Bedowra Zabeen, et al.

    Background: Long-acting insulin analogues are the standard of care for Type 1 diabetes (T1D) in high-income countries but remain inaccessible in many low-resource settings. Cost-effectiveness is a key consideration for their adoption. This analysis evaluated the cost-effectiveness of biosimilar insulin glargine (IGlar) versus neutral protamine Hagedorn (NPH) insulin in youth with T1D in Tanzania and Bangladesh. Methods: Data from the HumAn-1 trial informed a short-term economic model comparing NPH and IGlar over 12 months. The analysis, conducted from a health systems perspective, incorporated micro-costing data for insulin, injection supplies, blood glucose monitoring, and estimated hospitalization costs for complications. Effectiveness was based on a reduction in nocturnal hypoglycemia. In both countries, we calculated incremental cost-effectiveness ratios per quality-adjusted life year (QALY) gained in scenarios that compared IGlar against NPH across delivery devices (i.e. vials, cartridges, single-use pens). Results: IGlar was cost-effective compared to NPH when provided in cartridges in Bangladesh at a threshold of three times gross domestic product per capita. Other delivery devices in Bangladesh and all options in Tanzania were not cost-effective at current prices. If offered, IGlar vials would be cost-effective in Tanzania and Bangladesh if the price introduced was no more than 32% or 134% higher, respectively, than the current prices of NPH vials. Annual per patient costs and other cost-effectiveness thresholds were explored. Conclusion: In low-resource settings, IGlar can be a cost-effective alternative to NPH, largely due to reduced nocturnal hypoglycemia, but the delivery device for the insulin has a major impact on the costs and cost-effectiveness comparisons.

  • Top Cited Papers
    Open Access

    Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0

    by Graham D. Ogle, Fei Wang, Aveni Haynes, Gabriel A. Gregory, Thomas W. King, Kylie Deng, Dana Dabelea, Steven James, Alicia J. Jenkins, Xia Li, et al.


  • Open Access

    Etiologic Determinants and Characteristics of Diabetes in Haitian Youth (EDDHY Study)

    by Eddy Jean-Baptiste, Philippe Larco, Julia E Von Oettingen, Janelle A Noble, Steven J Mack, Ningyi Song, Harper R N Martin, Erik Rozemuller, Mark A Atkinson, Denira Govender, et al.

    Aims: Published information on youth‐onset diabetes in Haiti is scarce, with limited data available on diabetes autoimmunity and genetic susceptibility to the disease. We determined the anthropometric, metabolic, and immunological characteristics and human leukocyte antigen (HLA)‐associated risks in patients with youth‐onset diabetes. Methods: One hundred and ten subjects with type 1 diabetes (T1D) aged Results: Of the 110 patients, 54% were male. Onset age was 13.5 ± 4.2 years (range 2–21), and disease duration was 11.7 ± 8.1 months (range 0–24). Idiopathic T1D was found in 62 (56.4%) patients and was diagnosed at an older age than immune‐mediated T1D (14.4 ± 3.5 years vs., 12.3 ± 4.8 years, p = 0.01), with a higher BMI z‐score in patients aged p = 0.01). No correlation was found between immune‐mediated T1D and BMI z‐score. Diabetic ketoacidosis was present at diagnosis in 18 (16.4%) patients. Zinc transporter 8 autoantibodies (ZnT8A) were marginally more common in younger patients. Low FCP levels were found in 71 (64.5%) patients. Thyroid peroxidase antibodies (TPO‐Ab) and thyroglobulin antibodies (TG‐Ab) were positive in 1.1% and 2.2% of the patients, respectively. The alleles DRB1   ∗ 03:01 , DRB1   ∗ 09:01 , DQB1   ∗ 02:01 , and DQB1   ∗ 02:02 showed a significant T1D risk, whereas DRB1   ∗ 08:04 , DRB1   ∗ 15:03 , and DQB1   ∗ 06:02 were protective. Three DRB1~DQB1 haplotypes were strongly associated with T1D: DRB1   ∗ 03:01:01~DQB1   ∗ 02:01:01 , DRB1   ∗ 09:01:02~DQB1   ∗ 02:02:01 , both predisposing, and DRB1   ∗ 15:03:01~DQB1   ∗ 06:02:01 , protective . Conclusions: Idiopathic T1D is common among youth in Haiti. A significant proportion of all patients had preserved C‐peptide secretion. Overall, predisposing and protective HLA patterns were identified. Study results highlight the importance of distinguishing T1D endotypes within and between populations.

  • Open Access

    Complete HLA genotyping of type 1 diabetes patients and controls from Mali reveals both expected and novel disease associations

    by Janelle A. Noble, Stéphane Besançon, Assa Traore Sidibé, Erik H. Rozemuller, Maaike Rijkers, Fereshte Dadkhodaie, Helma de Bruin, Jannetje Kooij, Harper R. N. Martin, Graham D. Ogle, et al.

    HLA genotyping was performed on 99 type 1 diabetes (T1D) patients and 200 controls from Mali. Next‐generation sequencing of the classical HLA‐A, ‐B, ‐C, ‐DRB1, ‐DRB3, ‐DRB4, ‐DRB5, ‐DQA1, ‐DQB1, ‐DPA1, and ‐DPB1 loci revealed strong T1D association for all loci except HLA‐C and ‐DPA1. Class II association is stronger than class I association, with most observed associations predisposing or protective as expected based on previous studies. For example, HLA‐DRB1*03:01, HLA‐DRB1*09:01, and HLA‐DRB1*04:05 predispose for T1D, whereas HLA‐DRB1*15:03 is protective. HLA‐DPB1*04:02 (OR = 12.73, p = 2.92 × 10−05) and HLA‐B*27:05 (OR = 21.36, p = 3.72 × 10−05) appear highly predisposing, although previous studies involving multiple populations have reported HLA‐DPB1*04:02 as T1D‐protective and HLA‐B*27:05 as neutral. This result may reflect the linkage disequilibrium between alleles on the extended HLA‐A*24:02~HLA‐B*27:05~HLA‐C*02:02~HLA‐DRB1*04:05~HLA‐DRB4*01:03~HLA‐DQB1*02:02~HLA‐DQA1*02:01~HLA‐DPB1*04:02~HLA‐DPA1*01:03 haplotype in this population rather than an effect of either allele itself. Individual amino acid (AA) analyses are consistent with most T1D association attributable to HLA class II rather than class I in this data set. AA‐level analyses reveal previously undescribed differences of the HLA‐C locus from the HLA‐A and HLA‐B loci, with more polymorphic positions, spanning a larger portion of the gene. This may reflect additional mechanisms for HLA‐C to influence T1D risk, for example, through expression differences or through its role as the dominant ligand for killer cell immunoglobulin‐like receptors (KIR). Comparison of these data to those from larger studies and on other populations may facilitate T1D prediction and help elucidate elusive mechanisms of how HLA contributes to T1D risk and autoimmunity.


  • Open Access

    Correction to: The T1D Index: Implications of Initial Results, Data Limitations, and Future Development

    by Graham D. Ogle, Gabriel A. Gregory, Fei Wang, Thomas I. G. Robinson, Jayanthi Maniam, Dianna J. Magliano, Trevor John Orchard

  • Open Access

    The T1D Index: Implications of Initial Results, Data Limitations, and Future Development

    by Graham D. Ogle, Gabriel A Gregory, Fei Wang, Thomas Ig Robinson, Jayanthi Maniam, Dianna J Magliano, Trevor John Orchard

    Purpose of the Review: Current global information on incidence, prevalence, and mortality of type 1 diabetes (T1D) is limited, particularly in low- and middle-income countries. To address this gap in evidence, JDRF, Life for a Child, International Society for Pediatric and Adolescent Diabetes, and International Diabetes Federation have developed the T1D Index, which uses a Markov mathematical model, and machine learning and all available data to provide global estimates of the burden on T1D. This review assesses the methodology, limitations, current findings, and future directions of the Index. Recent Findings: Global prevalence was estimated at 8.4 million in 2021, with 1.5 million <20 years (y). T1D prevalence varied from 1.5 to 534 per 100,000, with T1D accounting for <0.1–17.8% of all diabetes in different countries. A total of 35,000 young people <25 y are estimated to have died at clinical onset of T1D from non-diagnosis. An estimated 435,000 people <25 y were receiving “minimal care.” Health-adjusted life years (HALYs) lost for individuals diagnosed with T1D at age 10 y in 2021 ranged from 14 to 55 y. Summary: These results show that interventions to reduce deaths from non-diagnosis, and improve access to at least an intermediate care level, are needed to reduce projected life years lost. The results have significant uncertainties due to incomplete data across the required inputs. Obtaining recent incidence, prevalence, and mortality data, as well as addressing data quality issues, misdiagnoses, and the lack of adult data, is essential for maintaining and improving accuracy. The index will be updated regularly as new data become available.


  • Insulin thermostability in a real-world setting

    by Sanket Pendsey, Steven James, Timothy J Garrett, Anders Bay Nord, Sharad Pendsey, Daniel Malmodin, Göran Karlsson, Jayanthi Maniam, Mark A Atkinson, Gun Forsander, et al.


  • Top Cited Papers

    Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

    by Gabriel A Gregory, Thomas I G Robinson, Sarah E Linklater, Fei Wang, Stephen Colagiuri, Carine de Beaufort, Kim C Donaghue, Jessica L Harding, Pandora L Wander, Xinge Zhang, et al.


  • Clinical features, biochemistry, and HLA ‐ DRB1 status in youth‐onset type 1 diabetes in Mali

    by Stéphane Besançon, Denira Govender, Assa Traore Sidibé, Janelle Annette Noble, Amagara Togo, Julie Ann Lane, Steven John Mack, Mark A. Atkinson, Clive Henry Wasserfall, Faizy Kakkat, et al.

    Limited information is available regarding youth-onset diabetes in Mali. We investigated demographic, clinical, biochemical, and genetic features in new diabetes cases in children and adolescents. The study was conducted at Hôpital du Mali in Bamako. A total of 132 recently-diagnosed cases <21 years were enrolled. Demographic characteristics, clinical information, biochemical parameters (blood glucose, HbA1c, C-peptide, glutamic acid decarboxylase-65 (GAD-65) and islet antigen-2 (IA2) autoantibodies) were assessed. DNA was genotyped for HLA-DRB1 using high-resolution genotyping technology. A total of 130 cases were clinically diagnosed as type 1 diabetes (T1D), one with type 2 diabetes (T2D), and one with secondary diabetes. A total of 66 (50.8%) T1D cases were males and 64 (49.2%) females, with a mean age at diagnosis of 13.8 ± 4.4 years (range 0.8-20.7 years) peak onset of 15 years. 58 (44.6%) presented in diabetic ketoacidosis; with 28 (21.5%) IA2 positive, 76 (58.5%) GAD-65 positive, and 15 (11.5%) positive for both autoantibodies. HLA was also genotyped in 195 controls without diabetes. HLA-DRB1 genotyping of controls and 98 T1D cases revealed that DRB1*03:01, DRB1*04:05, and DRB1*09:01 alleles were predisposing for T1D (odds ratios [ORs]: 2.82, 14.76, and 3.48, p-values: 9.68E-5, 2.26E-10, and 8.36E-4, respectively), while DRB1*15:03 was protective (OR = 0.27; p-value = 1.73E-3). No significant differences were observed between T1D cases with and without GAD-65 and IA2 autoantibodies. Interestingly, mean C-peptide was 3.6 ± 2.7 ng/ml (1.2 ± 0.9 nmol/L) in T1D cases at diagnosis. C-peptide values were higher than expected in those diagnosed as T1D and autoantibody rates lower than in European populations. It is quite possible that some cases have an atypical form of T1D, ketosis-prone T2D, or youth-onset T2D. This study will help guide assessment and individual management of Malian diabetes cases, potentially enabling healthier outcomes.


  • Incidence of type 1 diabetes in children in Dominican Republic, 2010–2019: A national collaborative study

    by Elbi Morla, Ammar Ibrahim, Graham D. Ogle, Steven James, Jayanthi Maniam, Rosario Almanzar, Carmen Rosario, Angela Matos, Lourdes Ruiz, Patricia Martinez, et al.

    The Dominican Republic has no recent data on type 1 diabetes (T1D) incidence in children. Therefore, a study was undertaken to determine this in persons aged <15 years (y). Data were collected on all new T1D diagnoses between 2010-2019 from the four institutions caring for children with T1D. Diagnosis was made according to standard criteria. No secondary ascertainment source was available. The trend and the effect of age and sex of T1D incidence was analyzed using Poisson regression. A total of 1224 new cases of T1D were diagnosed <15 y; mean ± standard deviation (range) 122 ± 12 (96-135) cases per year. Age at T1D diagnosis was 8.8 ± 3.7 y, with a significant female preponderance (n = 708, 57.8%, p < 0.001). When examined per 5-y age group, cases were consistently highest in 10-14 y, and lowest in 0-4 y in all study years. Mean crude T1D annual incidence was 4.3 (95% CI 3.5-5.1) per 100,000 population. There was no significant difference between incidence across the country's three departments (regions): Southeast (4.4 [3.4-5.7]/100,000 population), North (4.1 [2.9-5.6]), and Southwest (3.9 [2.4-5.9]). Mean standardized annual incidence was 4.1 (4.1-4.2) per 100,000 population, with no significant trend of increase over the study period. The incidence of T1D in children aged <15 y is relatively low in Dominican Republic, but consistent with the limited data from other countries in the region. However, the incidence is eight times higher than the previous estimate during 1995-1999. Ongoing surveillance is warranted.